Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Chinese Journal of Hematology ; (12): 667-671, 2023.
Article in Chinese | WPRIM | ID: wpr-1012210

ABSTRACT

Objective: To evaluate the efficacy and safety of bendamustine combined with pomalidomide and dexamethasone (BPD regimen) in the treatment of relapsed multiple myeloma (MM) with extramedullary disease. Methods: This open, single-arm, multicenter prospective cohort study included 30 relapsed MM patients with extramedullary disease diagnosed in seven hospitals including Qingdao Municipal Hospital. The patients were treated with BPD regimen from February 2021 to November 2022. This study analyzed the efficacy and adverse reactions of the BPD regimen. Results: The median age of the 30 patients was 62 (47-72) years, of which 18 (60% ) had first-time recurrence. The overall response rate (ORR) of the 18 patients with first-time recurrence was 100%, of which three (16.7% ) achieved complete remission, 10 (55.5% ) achieved very good partial remission (VGPR), and five (27.8% ) achieved partial remission (PR). The ORR of 12 patients with recurrence after second-line or above treatment was 50%, including zero patients with ≥VGPR and six patients (50% ) with PR. Three cases (25% ) had stable disease, and three cases (25% ) had disease progression. The one-year progression free survival rate of all patients was 65.2% (95% CI 37.2% -83.1% ), and the 1-year overall survival rate was 90.0% (95% CI 76.2% -95.4% ). The common grade 3-4 hematology adverse reactions included two cases (6.7% ) of neutropenia and one case (3.3% ) of thrombocytopenia. The overall adverse reactions are controllable. Conclusions: The BPD regimen has good efficacy and tolerance in relapsed MM patients with extramedullary disease.


Subject(s)
Humans , Middle Aged , Aged , Multiple Myeloma/drug therapy , Bendamustine Hydrochloride/therapeutic use , Prospective Studies , Dexamethasone/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use
2.
Journal of Experimental Hematology ; (6): 421-424, 2014.
Article in Chinese | WPRIM | ID: wpr-349697

ABSTRACT

The aim of this study was to investigate the effects of D-methionine (D-met) on the hematopoietic system injury in irradiated mice. C57BL/6 mice were divided into control group, irradiated group, 300 mg/kg D-met plus irradiation group and 1000 mg/kg D-met plus irradiation group. The control mice received sham irradiation, and the mice in remainder groups were exposed to 7.5 Gy; 1,4,8 Gy and 1 Gy of (137)Cs γ-ray respectively, were used to detect the survival rate, survival rate of bone marrow cells, WBC and its differential counts as well the colony formation ability in irradiated mice, respectively. The D-met was intraperitoneally injected to mice at 30 min before irradiation. The results showed that 300 and 1000 mg/kd D-met did not obviously enhance the survival rate of mice exposed to 7.5 Gy; the 10(-2),10(-3),10(-4) mol/L D-met significantly increased the survival rate of bone marrow cells in mice exposed to 1,4,8 Gy; 300 and 1000 mg/kg D-met even so increased the WBC count of peripheral blood in mice exposed to 1 Gy, but there was no statistical difference as compared with irradiated alone mice, moreover 300 and 1000 mg/kg D-met could obviously promote the colony formation ability of bone marrow cells in irradiated mice, the CFU-GM count was higher than that in 1 Gy irradiated mice (P < 0.05). It is concluded that the D-met can effectively mitigate the marrow cell injury resulted from irradiation, enhance the survival rate of bone marrow cells in irradiated mice, promote the recovery of hematopoietic function from radiation injury in mice.


Subject(s)
Animals , Mice , Bone Marrow Cells , Radiation Effects , Hematopoietic System , Radiation Effects , Leukocyte Count , Methionine , Pharmacology , Mice, Inbred C57BL , Radiation Injuries
3.
Journal of Experimental Hematology ; (6): 1361-1364, 2012.
Article in Chinese | WPRIM | ID: wpr-325259

ABSTRACT

This study was aimed to investigate the effect of arsenic trioxide (As(2)O(3)) alone and in combination with bortezomib (Bor) on proliferation and apoptosis of leukemia cell line K562, and to analyze the potential mechanism. K562 cells were treated with different concentrations of As(2)O(3) or Bor (alone or combination) for 24, 48 h. MTT method was used to detect the cell proliferation. After K562 cells were treated with 0.5 µmol/L As(2)O(3) alone or in combination with 10 nmoL/L Bor, the apoptosis rate and cell cycle were measured by flow cytometry, and the activity of NF-κB was analyzed by SP immunohistochemistry. The results indicated that the different concentrations of As(2)O(3) and Bor could inhibit the K562 cell proliferation in a time- and dose-dependent manners (P < 0.05). The IC(50) of Bor and As(2)O(3) in 48 h were 20 nmol/L and 0.6 µmol/L respectively. When K562 cells were treated with As(2)O(3) or Bor alone for 24 h, the apoptotic rate of K562 cells increased, and the apoptotic rate in combination group was higher than that in As(2)O(3) or Bor group. The cells were apparently arrested in G(2)/M phase in Bor group and G(0)/G(1) phase in As(2)O(3) group. The activity of NF-κB decreased significantly in As(2)O(3) or Bor group (P < 0.05), this effect was most significant in the combination group (P < 0.01). It is concluded that both As(2)O(3) and Bor can inhibit the proliferation and induce apoptosis of K562 cells, a synergistic effect can be observed when a low dose of As(2)O(3) combined with low dose of Bor. The different cell cycle block site and the decrease of activity of NF-κB may be one of the mechanisms underlying their synergic effect.


Subject(s)
Humans , Apoptosis , Arsenicals , Pharmacology , Boronic Acids , Pharmacology , Bortezomib , Cell Proliferation , Drug Synergism , K562 Cells , NF-kappa B , Metabolism , Oxides , Pharmacology , Pyrazines , Pharmacology
4.
Journal of Experimental Hematology ; (6): 863-866, 2012.
Article in Chinese | WPRIM | ID: wpr-278477

ABSTRACT

This study was aimed to explore the effects of hyperbaric oxygenation (HBO) alone or combined with As(2)O(3) on proliferation, apoptosis and expression of HIF-1a, VEGF, caspase-3 mRNA of K562 cells, and the molecular mechanism of As(2)O(3) enhancing the anti-leukemic effect of HBO so as to provide a scientific basis for clinical treatment of chronic myeloid leukemia. The effects of drugs on proliferation of K562 cells was assayed by MTT method, the apoptosis rate of K562 cells was detected by flow cytometry with Annexin V/PI double staining, the expressions of HIF-1a, VEGF, caspase-3 mRNA of K562 cells were determined by real-time quantitative PCR. The results showed that as compared with As(2)O(3) alone, HBO combined with As(2)O(3) could increase inhibitory rate of K562 cell proliferation, and enhance apoptotic effect, obviously down-regulate expressions of HIF-1a and VEGF mRNA, up-regulate expression of caspase-3 mRNA. The effect of HBO combined with As(2)O(3) was higher then effect of As(2)O(3) alone, and their effects were synergistic (P < 0.05). It is concluded that HBO combined with As(2)O(3) can increase the expression of caspase 3 mRNA and decrease the expression of HIF-1a and VEGF mRNA, which may be one of molecular mechanisms underlying their synergistic antileukemia efficacy.


Subject(s)
Humans , Apoptosis , Arsenicals , Pharmacology , Caspase 3 , Metabolism , Cell Proliferation , Hyperbaric Oxygenation , Hypoxia-Inducible Factor 1, alpha Subunit , Metabolism , K562 Cells , Vascular Endothelial Growth Factor A , Metabolism
5.
Acta Pharmaceutica Sinica ; (12): 395-399, 2011.
Article in Chinese | WPRIM | ID: wpr-348942

ABSTRACT

This study is to investigate the protective effects of the SB203580 against radiation induced mortality and intestinal injury of mice. A total of 67 male C57BL/6 mice (20.0-22.0 g) were matched according to body weight and randomly assigned to one of three groups: control, total body irradiation exposure (IR, 7.2 Gy) only, and IR (7.2 Gy) + SB203580 (15 mg x kg(-1)). 30 days survival rate was observed in the experiment. In intestinal injury experiment, the expression levels of caspase-3, Ki67, p53 and p-p38 were assayed in the mice intestine crypts. The results showed that the 30 days survival rate was 100% (control), 0 (IR) and 40% (IR+ SB203580), separately. Compared to the IR groups, the positive cells of caspase-3, p53 and p-p38 in crypt cells decreased 33.00%, 21.78% and 34.63%, respectively. The rate of positive cells of Ki67 increased 37.96%. Significant difference was found between all of them (P < 0.01). SB203580 potently protected against radiation-induced lethal and intestinal injury in mice, and it may be a potential radio protector.


Subject(s)
Animals , Male , Mice , Apoptosis , Radiation Effects , Caspase 3 , Metabolism , Enzyme Inhibitors , Pharmacology , Imidazoles , Pharmacology , Intestines , Metabolism , Pathology , Ki-67 Antigen , Metabolism , Mice, Inbred C57BL , Pyridines , Pharmacology , Radiation Injuries, Experimental , Metabolism , Mortality , Pathology , Radiation-Protective Agents , Pharmacology , Random Allocation , Tumor Suppressor Protein p53 , Metabolism , Whole-Body Irradiation , p38 Mitogen-Activated Protein Kinases , Metabolism
6.
Journal of Experimental Hematology ; (6): 395-398, 2011.
Article in Chinese | WPRIM | ID: wpr-244915

ABSTRACT

This study was aimed to explore the expression of B cell-activating factor of TNF family (BAFF) and B cell lymphoma/leukemia-2 (BCL-2) in bone marrow mononuclear cells (BMMNC) of multiple myeloma (MM) and the significance of BAFF and BCL-2 for occurrence, development and prognosis of MM. The bone marrow of 40 cases of MM and 10 healthy persons was collected, the mononuclear cells (MNC) were isolated, the expression of BAFF and BCL-2 mRNA in BMMNC was detected by real-time PCR; the plasma was simultaneously collected and the β2-MG level was determined; the clinical staging of MM patients was performed according to Durie-Salmon (D-S) staging criterion. The results indicated that the expression level of BAFF and BCL-2 mRNA in MM patients increased, as compared with normal controls, the difference was statistical significant (p < 0.05); the expression level of BAFF and BCL-2 mRNA in plateau stage after treatment obviously decreased. The expression level of BAFF and BCL-2 mRNA in relapsed/refractory MM patients was significantly higher than that in normal controls and patients reached plateau stage (p < 0.05), there was no statistically significant difference between newly diagnosed and relapsed/refractory MM patients (p > 0.05). The expression of BAFF and BCL-2 mRNA related with D-S staging and β2-MG level. It is concluded that the expression levels of BAFF and BCL-2 mRNA increase, moreover the expression levels of BAFF and BCL-2 mRNA in newly diagnosed and relapsed/refractory MM patients are higher than those in patients reached plateau stage, which suggest the BAFF and BCL-2 may be involved in occurrence and development of MM; the relation of expression level of BAFF and BCL-2 mRNA to MM load is positive, which indicates the expression level of BAFF and BCL-2 mRNA may be a new indicator for evaluating the prognosis of MM patients.


Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , B-Cell Activating Factor , Genetics , Metabolism , Case-Control Studies , Lymphoma, B-Cell , Genetics , Multiple Myeloma , Diagnosis , Genetics , Prognosis , Proto-Oncogene Proteins c-bcl-2 , Genetics , Metabolism , RNA, Messenger , Genetics
7.
Journal of Southern Medical University ; (12): 2288-2294, 2010.
Article in Chinese | WPRIM | ID: wpr-323680

ABSTRACT

<p><b>OBJECTIVE</b>To study the effects of pulsed magnetic field on insulin-like growth factor-1 (IGF-1) level in the cerebrospinal fluid (CSF) and the association of IGF-1 alterations with the activities of daily living (ADL) of patients with brain injury.</p><p><b>METHODS</b>Sixty-five patients with brain injury were divided randomly into the control group (n=30) and magnetic therapy group (n=35), both receiving conventional therapy and in the latter group, daily pulsed magnetic field treatment (20-40 mT, 50 Hz, 20 min per time, 1 time per day) for 14 consecutive days were administered. On the first and 14th days of the treatment, 2 ml CSF was collected from the cases patients for IGF-1 measurement by radioimmunoassay, and Barthel index (BI) was used to assess the ADL of the patients.</p><p><b>RESULTS</b>After a 14-day treatment, IGF-1 level in the CSF were significantly increased in the magnetic group in comparison with the level before the treatment and with those in the control group (P<0.05). IGF-1 in the CSF underwent no significant changes in the control group (P>0.05). The scores of BI increased significantly in both groups after the treatment (P<0.01), but the increment was more obvious in the magnetic therapy group (P<0.05). A significant positive correlation was found between IGF-1 level in the CSF and BI in these patients (r=0.283, P=0.022).</p><p><b>CONCLUSION</b>Pulsed magnetic field might increase IGF-1 level in the CSF of patients with brain injury to promote the recovery of the patients ADL, suggesting its potential clinical value in the treatment of brain injury.</p>


Subject(s)
Adult , Female , Humans , Male , Middle Aged , Brain Injuries , Cerebrospinal Fluid , Rehabilitation , Therapeutics , Insulin-Like Growth Factor I , Cerebrospinal Fluid , Magnetic Fields , Recovery of Function
8.
Journal of Southern Medical University ; (12): 598-599, 2008.
Article in Chinese | WPRIM | ID: wpr-280139

ABSTRACT

<p><b>OBJECTIVE</b>To study the changes of insulin-like growth factor-I (IGF-I) in focal cerebral ischemical reperfusion injury model.</p><p><b>METHODS</b>Focal cerebral ischemia was induced in rats using filament method, and the expressions of IGF-I was detected with immunohistochemical staining.</p><p><b>RESULTS</b>The expression of IGF-I was very low in normal brain tissues, but increased in the infracted area and penumbra after cerebral ischemia. The expressions of IGF-I reached the peak level of 14.83-/+0.48 at days 3 after reperfusion.</p><p><b>CONCLUSION</b>Focal cerebral ischemia reperfusion injury enhances the expression of endogenous IGF-I.</p>


Subject(s)
Animals , Female , Male , Rats , Immunohistochemistry , Infarction, Middle Cerebral Artery , Metabolism , Pathology , Insulin-Like Growth Factor I , Ischemic Attack, Transient , Metabolism , Random Allocation , Rats, Sprague-Dawley , Reperfusion Injury , Metabolism
SELECTION OF CITATIONS
SEARCH DETAIL